Poolbeg Pharma PLC
OTC: POLBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeremy Skillington
- Employees
- 15
- Headquarters
- London, United Kingdom
- IPO year
- 2022
- Market cap
- $64.8M
- Website
- https://www.poolbegpharma.com
Loading POLBF…
Loading profile data…Frequently asked questions about POLBF
What does Poolbeg Pharma PLC (POLBF) do?
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class R...
Where does POLBF trade?
Poolbeg Pharma PLC (POLBF) trades on the Other OTC.
What sector is POLBF in?
Poolbeg Pharma PLC (POLBF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Poolbeg Pharma PLC?
Jeremy Skillington is the chief executive officer of Poolbeg Pharma PLC (POLBF).
Where is Poolbeg Pharma PLC headquartered?
Poolbeg Pharma PLC is headquartered in United Kingdom.
Does POLBF pay a dividend?
Poolbeg Pharma PLC (POLBF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did POLBF go public?
Poolbeg Pharma PLC (POLBF) completed its initial public offering in 2022.